IN THE SPOTLIGHT

Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC

Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC

Vebreltinib effective in MET-amplified NSCLC

Vebreltinib effective in MET-amplified NSCLC

Navigating the Evolving Landscape of EGFR-Mutated NSCLC

Navigating the Evolving Landscape of EGFR-Mutated NSCLC

Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

Identifying and validating SMARCAL1 as a prognostic and immunotherapy predictive biomarker for NSCLC

肺癌之声丨关印教授:当 HER2 突变 NSCLC 治疗迈入深水区,如何构建个体化诊疗「三维地图」_腾讯新闻

肺癌之声丨关印教授:当 HER2 突变 NSCLC 治疗迈入深水区,如何构建个体化诊疗「三维地图」_腾讯新闻

Unravelling the molecular genetics and epigenetic regulation of lung cancer vis a vis non-small cell lung cancer (NSCLC) for a targeted approach towards novel therapeutic strategies: a review

Unravelling the molecular genetics and epigenetic regulation of lung cancer vis a vis non-small cell lung cancer (NSCLC) for a targeted approach towards novel therapeutic strategies: a review

Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS

Comparative Toxicovigilance of Capmatinib and Tepotinib in NSCLC: Respiratory Signal Detection and Adverse Event Profiling via FAERS